Clinical Trials Logo

Stargardt's Macular Dystrophy clinical trials

View clinical trials related to Stargardt's Macular Dystrophy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02941991 Completed - Clinical trials for Stargardt's Macular Dystrophy

A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Start date: January 16, 2013
Phase:
Study type: Observational

The purpose of this study is to evaluate the long term safety and tolerability of hESC-RPE cellular therapy in patients with advanced SMD from 1 to 5 years following the surgical procedure to implant the hESC-RPE cells.

NCT ID: NCT02445612 Completed - Clinical trials for Stargardt's Macular Dystrophy

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Start date: July 11, 2012
Phase:
Study type: Observational

The purpose of this study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced Stargardt's Macular Dystrophy (SMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.

NCT ID: NCT01625559 Completed - Clinical trials for Stargardt's Macular Dystrophy

Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

Start date: September 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD

NCT ID: NCT01469832 Completed - Clinical trials for Stargardt's Macular Dystrophy

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Start date: December 13, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is: To evaluate the safety and tolerability of RPE cellular therapy in patients with SMD . To evaluate potential efficacy endpoints to be used in future studies RPE cellular therapy.

NCT ID: NCT01345006 Completed - Clinical trials for Stargardt's Macular Dystrophy

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

Start date: June 16, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with Stargardt's Macular Dystrophy (SMD).